ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics.
Menlo Park, CA & Dallas, TX
- Tweets 171
- Following 152
- Followers 586
- Likes 23
Better delivery platforms can unleash the true potential of genetic medicines. These must deliver drugs beyond the liver – to the lungs, spleen, and beyond.
Learn how we are powering the next wave of genetic medicines through superior delivery: recodetx.com/
9
We’re at the @mRNAConference this week. Come join our session at 3:10pm ET where David Lockhart, our President and CSO, will be talking about our SORT LNP-formulated mRNA for the treatment of #PrimaryCiliaryDyskinesia.
1
7
We want to say thank you to everyone who participated in the #NACFC2022 conference this year.
We’re truly inspired by the passionate people we met who are carrying forward research to treat the thousands of people living with #CysticFibrosis.
1
3
This month, we’ll be participating in the @CreditSuisse and @Stifel Healthcare Conferences. We’re looking forward to sharing more about our novel #genetic #medicines delivery platform and pipeline of disease-modifying #mRNA & gene correction therapeutics. recodetx.com/recode-therapeu…
We’re excited to attend #NACFC2022 this year with other members of the #CysticFibrosis community. Please visit us at booth #1020 to learn more about our investigational therapy for CF patients who have nonsense mutations & do not respond to currently approved CFTR modulators.
2
3
We’re very proud to have been nominated for the 2022 #PrixGalien award for “Best Startup in the Pharmaceutical or Biotechnology Industry.” Thank you @GalienFdn for this honor and congratulations to all of this year’s winners and nominees for your work to improve human health!
2
3
This #LungHealthDay, we recognize the importance of #LungHealth and show support to those living with a rare lung condition.
At Recode, we aim to improve the lives of these patients by developing genetic medicines with superior delivery. Learn more at recodetx.com/pipeline/
1
2
Did you know October is #HealthyLungMonth?
We wanted to take this opportunity to shed some light on the research we are undertaking to improve the lives of patients with #CysticFibrosis, a rare condition that affects the lungs.
1
#PrimaryCiliaryDyskinesia, or #PCD, is challenging to diagnose leading to both missed diagnosis and misdiagnosis.
Although there is no treatment for PCD, an early diagnosis can help protect and delay damage to the lungs.
Source: nhlbi.nih.gov/health/primary….
#PCDAwarenessMonth
1
4
7
#CysticFibrosis (CF) can make it very difficult to breathe. This #HealthyLungMonth, we’re raising awareness about this disease and the way in which it affects the lungs. Learn more about CF and our approach to a CFTR mRNA therapy at recodetx.com/pipeline/.
1
October is #PCDAwarenessMonth. Have you heard of PCD?
- I know someone who has it.
- No. What is it?
1
1
This week at EMBO #Cilia2022 in Cologne, our own Mirko Hennig, presented important preclinical data that showed our investigational inhaled DNAI1 mRNA treatment for #PCD has low immune reactivity, rescues ciliary function & results in long-lasting functional recovery.
7
This week, our own @angelemaki attended the @FierceBiotech Summit to celebrate ReCode being named one of 2022’s #Fierce15 most promising early stage biotechs. We are honored & will continue to be #fierce in our mission as we usher in a new era of possibility for #geneticmedicine
1
This week, our CEO @SulimanShehnaaz joined fellow leaders and journalists at @Bayer’s U.S. Science & Innovation Forum to discuss the risks and rewards of transformative biotech. We're proud to be part of a conversation that is changing the scientific landscape for the better!
6
We’re thrilled to announce @FierceBiotech has named @ReCodeTx as one of 2022’s Fierce 15 biotech companies, designating it as one of the most promising early-stage companies in the industry. Congratulations to all our fellow winners and all those who were nominated!
2
4
22
Attending the 20th annual @MorganStanley Global Healthcare Conference? Don't miss the chance to hear an update on ReCode’s corporate vision and progress from our CEO @SulimanShehnaaz on Tuesday, Sep. 13, at 8:00am ET. For more details click here: bwnews.pr/3AS75dr
4
#DYK that #PCD is often under-recognized & diagnosed as asthma, bronchitis or bronchiectasis of unknown cause? As a result, infection & inflammation eventually lead to bronchiectasis in almost all adults w/ #PCD. We’re working to address this. Learn more: bit.ly/3PPVyld
1
Today we’re spotlighting ReCode #ValueChampion Linda Lee Smith, senior manager of people operations. She represents our value, “Be curious, be kind, be yourself”. Linda Lee brings ReCode together, making sure everyone feels like they belong. Thanks for your kindness, Linda Lee!
Today we’re spotlighting ReCode #ValueChampion Daniella Ishimaru, PhD, a principal scientist. Daniella embodies our value, “Act with urgency”. When her team needed help, she immediately stepped up to find answers to pre-clinical experiments. Thanks for your leadership, Daniella!
2
We had a great time at the #mRNA-Based Therapeutics Summit last week. Arunan Kaliyaperumal, VP of preclinical biology, & David Liston, senior scientist, spoke about strategies for pre-clinical safety & bioanalytic studies to evaluate inhaled mRNA therapy. Thanks to all involved!
1
We are honored to have been nominated by the @GalienFdn for the 2022 #PrixGalien Startup in Biotech award, which recognizes and supports innovation worldwide. Learn more here: prn.to/3b8yyPr
1
ReCode is expanding its Selective Organ Targeting (SORT) LNP platform to include mRNA and gene correction therapeutics for central nervous system (CNS), lung, liver and oncology indications, in addition to our lead #CF and #PCD programs. Learn more: recodetx.com/pipeline/
1
1
Looking for a new, impactful role? As we diversify our pipeline and continue to advance our lead programs on #CysticFibrosis and #PrimaryCiliaryDyskinesia into the clinic, we’re quickly growing and would love to meet you. ReCode your future here: recodetx.com/careers/
2
Today we’re #spotlighting ReCode Values Champion Lulu Wang, a senior research associate who demonstrates our value, Solve Together. Lulu is an in vivo pharmacologist who collaborates across functional experts to unlock the team’s greatest potential. Thank you, Lulu!
1
We’re excited to unveil ReCode’s new logo & website. Check out our new site to follow our progress or learn more about how we’re changing the future of #geneticmedicine: recodetx.com/
2
We welcome the addition of our new investors and Board members who support our mission to power the next wave of genetic medicines through superior delivery.
1
6
#spotlight: This week's Values Champion is Molly Murphy, an R&D program manager who embodies our value: Think it. Own it. Do it. She takes bold initiative by consistently securing research tools on the programs she leads when times get tough. Thank you for everything you do!
Happy #PrideMonth! We support the #LGBTIQ+ community and celebrate diversity, identity, and belonging every day, everywhere.
1
#DidYouKnow that there is no available treatment for primary ciliary dyskinesia, only treatment for its symptoms? We’re working to change that for people living with this lung disease. Learn more about our disease-modifying approach at recodetx.com/#purpose
1
1
During #ProfessionalWellnessMonth, we’re reflecting on the importance of our employees’ holistic health. Empowering every person to be curious, be kind & be themselves are core to our values at ReCode. We very much appreciate our team members who are bringing our mission to life.
May is #CFAwarenessMonth. #ICYMI: Here are the Top 10 Cystic Fibrosis Stories of 2021 - we’re proud to be working toward transformative mRNA-based therapies for #CysticFibrosis. Read more here: bit.ly/3F1wQYV
We talked about novel mRNA-based therapeutic approaches to #CysticFibrosis and #PrimaryCiliaryDyskinesia treatment this week at #ATS2022. @atscommunity thanks for having us! Browse our poster presentations here: recodetx.com/news/presentati…
2
8
Today ReCode presented preclinical data on its mRNA-based program for #CF that confirms the ability of ReCode’s selective organ targeting (SORT) lipid nanoparticle (#LNP) platform to improve rescue of CFTR function across multiple genotypes. bit.ly/recode-CF #ATS2022
6
ReCode presented preclinical data on its inhaled mRNA therapeutic program in #PCD which showed our Selective Organ Targeting (SORT) #LNP formulation was successfully & directly delivered to lungs with no significant exposure to other tissues. See bit.ly/-recode #ATS2022
2
Find us at the Moscone Center at #ATS2022 on May 15 and 18! Looking forward to reconnecting with the ATS community in San Francisco. Poster and location details here: bit.ly/3Pc9YfH
#lunghealth #PCD #PrimaryCiliaryDyskinesia #CF #CysticFibrosis #ReCodeTx
Fantastic article in @statnews on the science and history of #lipidnanoparticles and their use in #genetherapy. Thank you @MeganMolteni: bit.ly/stat-lnps
In 10 days, we’ll be discussing ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) delivery platform incorporated into novel treatments for #PrimaryCiliaryDyskinesia, #CysticFibrosis, and beyond at #ATS2022. Hope to see you there! bwnews.pr/3kx17Hg
1
Join us at #ATS2022! We’ll be presenting new preclinical data on ReCode’s mRNA-based therapeutic programs that target the underlying genetic causes of #PCD and #CF at the @atscommunity conference on May 15 and 18. bwnews.pr/3kx17Hg
1
#ICYMI: Our CEO, Shehnaaz Suliman, M.D., M.B.A., was recently featured on @GENbio's program “Close to the Edge” with host @AlexWestchester! Check out the episode on Gen Edge to hear about her storied #career and the future of #ReCodeTx: piped.video/zhj-RKbdSl4?t=18.
2
3
Today, we’re #spotlighting @angelemaki, Ph.D., our Senior Vice President, Business Development. She is an accomplished BD executive with nearly 20 years of deal-making and corporate venture experience, and leads our business development strategy and execution.
2
We’re looking to #hire a Principal Scientist, Gene Correction to build the internal gene-editing platform for translational research to develop innovative new therapeutics for rare diseases. Explore all open positions at: bit.ly/3iPcUzL
#nowhiring #biotech #lifescience
2
We're #hiring a Head of Quality who will establish risk-based strategies and lead #GXP quality systems. If you have these skills and want to work for a pioneering company in #RNA drug development, kick off a new #career with #ReCodeTx: bit.ly/3MlxPI7
#nowhiring #jobs
On #WorldHealthDay, join us in helping raise awareness of the actions that we need to take to keep humans and the planet healthy. Get more information & resources from the @WHO:
bit.ly/3NBejrK
#WorldHealthDay2022 #HealthierTomorrow
1
2
2022 will be an exciting year for #LNPs and #genetic medicine development. Hear more from our #leadership team in one of the latest @PharmaScrip Asks series: bit.ly/3pvKA9a
#RNA #raredisease #ScripAsks
1
What better way to kick off the Spring season than by springing into a new #career with #ReCodeTx? Our company is #hiring and looking to add a #director in #RNA production.
Learn more and apply now: bit.ly/3IyniHk
#nowhiring #biotech #lifescience #hire
3
1
There’s still time to register! Join the @lsxleaders World Congress this week and hear from Angele Maki, Ph.D., our SVP of Business Development on the innovations our company are making in #RNA medicines.
Details on joining the event here: bit.ly/35ls90o
#RNAleaders
1
Interested in catching up with #ReCodeTx’s latest #business and #pipeline updates? We’ll be participating in @Oppenheimer’s Annual #Healthcare Conference next week. All details on attending and viewing here: bwnews.pr/3vXUe8V
#RNA #LNP
1